Polaris Greystone Financial Group LLC Purchases 1,600 Shares of Pfizer Inc. (NYSE:PFE)

Polaris Greystone Financial Group LLC grew its position in Pfizer Inc. (NYSE:PFE) by 19.7% during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 9,729 shares of the biopharmaceutical company’s stock after purchasing an additional 1,600 shares during the quarter. Polaris Greystone Financial Group LLC’s holdings in Pfizer were worth $426,000 as of its most recent filing with the SEC.

Several other large investors have also recently bought and sold shares of the company. BKD Wealth Advisors LLC raised its stake in shares of Pfizer by 2.5% during the fourth quarter. BKD Wealth Advisors LLC now owns 104,315 shares of the biopharmaceutical company’s stock worth $4,553,000 after acquiring an additional 2,561 shares in the last quarter. Advisors Capital Management LLC boosted its stake in Pfizer by 156.0% in the 4th quarter. Advisors Capital Management LLC now owns 52,143 shares of the biopharmaceutical company’s stock worth $2,276,000 after purchasing an additional 31,775 shares in the last quarter. Joel Isaacson & Co. LLC boosted its stake in Pfizer by 71.1% in the 4th quarter. Joel Isaacson & Co. LLC now owns 65,093 shares of the biopharmaceutical company’s stock worth $2,791,000 after purchasing an additional 27,058 shares in the last quarter. PFG Advisors boosted its stake in Pfizer by 40.6% in the 4th quarter. PFG Advisors now owns 9,321 shares of the biopharmaceutical company’s stock worth $404,000 after purchasing an additional 2,690 shares in the last quarter. Finally, Gemmer Asset Management LLC boosted its stake in Pfizer by 3.6% in the 4th quarter. Gemmer Asset Management LLC now owns 29,532 shares of the biopharmaceutical company’s stock worth $1,289,000 after purchasing an additional 1,017 shares in the last quarter. 71.81% of the stock is currently owned by institutional investors.

In related news, major shareholder Pfizer Inc acquired 50,000 shares of the firm’s stock in a transaction on Monday, May 13th. The stock was bought at an average cost of $17.00 per share, with a total value of $850,000.00. The acquisition was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Alexander R. Mackenzie sold 30,000 shares of the stock in a transaction that occurred on Thursday, June 20th. The stock was sold at an average price of $44.00, for a total value of $1,320,000.00. Following the transaction, the insider now directly owns 80,094 shares of the company’s stock, valued at $3,524,136. The disclosure for this sale can be found here. Corporate insiders own 0.09% of the company’s stock.

PFE has been the subject of a number of recent analyst reports. Goldman Sachs Group reissued a “buy” rating and issued a $49.00 target price on shares of Pfizer in a research report on Monday, June 17th. UBS Group reiterated a “neutral” rating and set a $43.00 price objective on shares of Pfizer in a research note on Monday, August 5th. Barclays restated a “hold” rating and issued a $41.00 price target on shares of Pfizer in a research note on Thursday, May 9th. JPMorgan Chase & Co. set a $46.00 price target on Pfizer and gave the stock a “neutral” rating in a research note on Monday, July 29th. Finally, Morgan Stanley downgraded Pfizer from an “overweight” rating to an “equal weight” rating and lowered their target price for the company from $48.00 to $40.00 in a research report on Tuesday, July 30th. Fifteen investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus target price of $46.24.

Shares of Pfizer stock traded down $0.52 during trading hours on Friday, hitting $36.35. The company’s stock had a trading volume of 21,609,556 shares, compared to its average volume of 31,392,730. Pfizer Inc. has a twelve month low of $35.86 and a twelve month high of $46.47. The company’s fifty day simple moving average is $42.02. The company has a market cap of $203.38 billion, a PE ratio of 12.12, a price-to-earnings-growth ratio of 2.92 and a beta of 0.63. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.27 and a current ratio of 1.54.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Monday, July 29th. The biopharmaceutical company reported $0.80 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.75 by $0.05. Pfizer had a return on equity of 27.57% and a net margin of 23.58%. The firm had revenue of $13.26 billion for the quarter, compared to the consensus estimate of $13.43 billion. During the same quarter in the previous year, the business earned $0.77 EPS. The company’s quarterly revenue was down 1.5% compared to the same quarter last year. Equities analysts predict that Pfizer Inc. will post 2.8 earnings per share for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 3rd. Stockholders of record on Friday, August 2nd will be given a dividend of $0.36 per share. The ex-dividend date is Thursday, August 1st. This represents a $1.44 annualized dividend and a dividend yield of 3.96%. Pfizer’s dividend payout ratio is currently 48.00%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.

Recommended Story: What is a portfolio manager?

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.